Angiogenesis plays a critical role in tumor aggressiveness, and a lot of anti-angiogenic agents have been used in clinical therapy. The therapeutic efficacy of peptides are generally restricted by the short in vivo life-time, thus, we were interested in developing a novel albumin-based and maleimidopropionic acid-conjugated peptide to prolong the half-life and improve the anti-tumor effect.

中文翻译：

---

具有延长的半衰期和增加的体内抗肿瘤功效的新型白蛋白基和马来酰亚胺基丙酸缀合的肽的开发

血管生成在肿瘤侵袭性中起关键作用，并且许多抗血管生成剂已用于临床治疗中。肽的治疗功效通常受到体内寿命短的限制，因此，我们有兴趣开发一种新型的基于白蛋白和马来酰亚胺基丙酸偶联的肽，以延长半衰期并改善抗肿瘤效果。